- Firsocostat
-
- $88.00 / 1mg
-
2024-11-19
- CAS:1434635-54-7
- Min. Order:
- Purity: 98.46%
- Supply Ability: 10g
- NDI-010976
-
- $0.00 / 1KG
-
2022-01-14
- CAS:1434635-54-7
- Min. Order: 1KG
- Purity: 97.4%
- Supply Ability: 100 tons
- NDI-010976
-
- $7.00 / 1KG
-
2019-07-06
- CAS:1434635-54-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kG
|
| | NDI-010976 Basic information |
| Product Name: | NDI-010976 | | Synonyms: | NDI-010976;(R)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanoicacid;ND-630;(R)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,2-dihydrothieno[2,3-d]pyrimidin-3(4H)-yl)-2-methylpropanoic acid;EOS-61252;GS0976;CPDB5078;(R)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,2-dihydrothieno[2,3- | | CAS: | 1434635-54-7 | | MF: | C28H31N3O8S | | MW: | 569.63 | | EINECS: | | | Product Categories: | API | | Mol File: | 1434635-54-7.mol |  |
| | NDI-010976 Chemical Properties |
| Boiling point | 779.0±70.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:75.0(Max Conc. mg/mL);131.66(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);17.56(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);5.27(Max Conc. mM) | | form | A crystalline solid | | pka | 3.66±0.10(Predicted) | | color | White to light yellow |
| | NDI-010976 Usage And Synthesis |
| Description | ND-630 is an allosteric inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits ACC1 and ACC2 activity (IC50s = 2.1 and 6.1 nM, respectively, for the human enzymes). It is selective for ACC over 101 enzymes, receptors, growth factors, transporters, and ion channels up to a concentration of 10 μM. ND-630 prevents dimerization of ACC by interacting within the phosphopeptide-acceptor and dimerization site. It reduces fatty acid synthesis (EC50s = 66 and 9 nM in 10% FBS and serum-free media, respectively) and increases fatty acid oxidation in HepG2 cells. ND-630 reduces hepatic steatosis in a rat model of diet-induced obesity and in Zucker diabetic rats. It also improves insulin secretion stimulated by glucose and reduces hemoglobin A1c levels by 0.9% in Zucker diabetic rats. | | Uses | Firsocostat or ND-630 (CAS# 1434635-54-7) is an inhibitor of acetyl-coA carboxylase and may favorably affect the morbidity and mortality associated with obesity, diabetes, and fatty liver disease from reduced hepatic steatosis, improved insulin sensitivity, and modulation of dyslipidemia. |
| | NDI-010976 Preparation Products And Raw materials |
|